Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes.

This is a House of Representatives resolution (H. Res. 685) introduced in the 119th Congress that expresses support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening and urges professional medical associations and guideline-setting bodies to update their recommendations accordingly. The resolution notes that APS can raise the risk of blood clots and pregnancy complications, including miscarriages and stillbirths, and it argues that routine APS testing could detect cases earlier and allow treatment with blood thinners. It emphasizes that current guidelines typically recommend APS testing only after certain unexplained pregnancy losses. The measure is non-binding and does not create new law or funding; it simply signals support and a call to professional bodies to change guidelines. It was introduced in the House and referred to the Committee on Energy and Commerce.